Our faculty research broadens the knowledge of kidney disease.
A catalog of genetic loci associated with kidney function from analyses of a million individuals
Chronic kidney disease (CKD) is responsible for a public health burden with multi-systemic complications. Through trans-ancestry meta-analysis of genome-wide association studies of estimated glomerular filtration rate (eGFR) and independent replication (n = 1,046,070), we identified 264 associated loci (166 new). Of these, 147 were likely to be relevant for kidney function on the basis of associations with the alternative kidney function marker blood urea nitrogen (n = 416,178). Pathway and enrichment analyses, including mouse models with renal phenotypes, support the kidney as the main target organ.
Albuminuria, the HDL (High-Density Lipoprotein) Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus.
Albuminuria is an important risk factor for cardiovascular disease in diabetes mellitus. We determined whether albuminuria associates with alterations in the proteome of HDL (high-density lipoprotein) of subjects with type 1 diabetes mellitus and whether those alterations associated with coronary artery calcification.
Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience
Glomerular hyperfiltration has been considered to be a contributing factor to the development of diabetic kidney disease (DKD). To address this issue, we analyzed GFR follow-up data on participants with type 1 diabetes undergoing 125I-iothalamate clearance on entry into the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications study.
Association of Serum Uromodulin With ESKD and Kidney Function Decline in the Elderly: The Cardiovascular Health Study
Uromodulin is released by tubular epithelial cells into the serum and lower levels are associated with more severe interstitial fibrosis and tubular atrophy. Low serum uromodulin (sUMOD) levels are associated with mortality and cardiovascular disease. However, little is known about the association of sUMOD levels with long-term kidney outcomes in older adults, a population with a high prevalence of interstitial fibrosis and tubular atrophy.
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease
The pandemic of diabetes has become a global emergency. Despite increasing knowledge about diabetes prevention, this knowledge has not translated into action that effectively reduces diabetes prevalence in communities. The global picture projects an increase in people living with diabetes, from 425 million in 2017 to nearly 630 million by 2045, 1 and such an increase also means more people with diabetes complications. Chronic kidney disease develops in almost half of people with type 2 diabetes and is the leading cause of end-stage kidney disease worldwide.
Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease
Data on rates of heart failure (HF) hospitalizations, recurrent hospitalizations, and outcomes related to HF hospitalizations in chronic kidney disease (CKD) are limited. This study examined rates of HF hospitalizations and re-hospitalizations within a large CKD population and evaluated the burden of HF hospitalizations with the risk of subsequent CKD progression and death.
A turning point for chronic kidney disease in diabetes
The Study Of Diabetic Nephropathy with Atrasentan (SONAR) in The Lancet demonstrates a turning point in trial innovation.12 This double-blind, randomised, placebo-controlled trial tested the endothelin A receptor antagonist atrasentan in patients with chronic kidney disease and type 2 diabetes using an enrichment design to select participants on the basis of drug tolerance for safety and responder status for efficacy.
Comparative Safety of Phosphate Binders Without Proven Efficacy-How Did We Get Here?
Consistent associations of a circulating marker with disease, supportive mechanistic evidence, and available drugs to modify the marker constitute a reasonable starting point for conducting randomized trials of clinical outcomes. Yet, clinical trials based on such evidence often fail to demonstrate clinical benefit from modifying the marker of interest. Initial studies of hyperphosphatemia in kidney disease did not engender informative trials of clinical outcomes, and to our knowledge, there are no randomized clinical trial data of clinical benefits of any phosphate binder in patients with ESRD compared with no treatment with phosphate binders.
Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis
Previous research has implicated dysregulation of phosphate metabolism and calcium-phosphate solubilization in cardiovascular calcification, but epidemiologic studies evaluating longitudinal associations with valvular or annular calcification by computed tomography (CT), a highly sensitive imaging modality, are lacking. Our primary aim was to investigate the associations of mineral biomarkers with incidence and progression of aortic valve calcification (AVC) and mitral annular calcification (MAC).
CJASN and Disclosure of Conflicts of Interest
Although recognizing the primacy of authors in fully reporting conflicts of interest, journals also have the responsibility of clearly articulating their policy on conflicts of interest and possible consequences for failure to adhere to such policy. CJASN is very mindful of its responsibility in ensuring the disclosure of conflicts of interest by authors for the work that we publish.